Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00246753
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
lapatinib ditosylate
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
[object Object]